DBV Technologies
Develops epicutaneous immunotherapy (EPIT) patch technology for food allergies.
DBV | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417345 (+3 more)
- LEI:
- 969500PVBQFWQKVDMD80
- Country:
- France
- Address:
- 107 AVENUE DE LA REPUBLIQUE, 92320 CHATILLON
- Sector:
- Manufacturing
Description
DBV Technologies is a clinical-stage biopharmaceutical company developing treatments for food allergies and other immunological diseases. The company's core technology is Viaskin®, a proprietary investigational platform based on epicutaneous immunotherapy (EPIT). This non-invasive patch technology is designed to re-educate the immune system by delivering minimal amounts of antigens through intact skin. DBV's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergies in pediatric patients. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, with the platform holding potential for applications beyond food allergies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-11-09 07:30 |
DBV Technologies to Highlight New Clinical Data at ACAAI 2022
|
English | 224.1 KB | ||
| 2022-11-03 21:30 |
DBV Technologies Reports Third Quarter Financial Results and Business Update
|
English | 382.0 KB | ||
| 2022-11-03 21:30 |
DBV Technologies publie ses résultats financiers du troisième trimestre 2022 et…
|
French | 296.1 KB | ||
| 2022-10-31 21:30 |
DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a B…
|
English | 203.4 KB | ||
| 2022-10-31 21:30 |
DBV Technologies présente ses résultats financiers du troisième trimestre 2022 …
|
French | 217.3 KB | ||
| 2022-10-20 22:30 |
Monthly information regarding the total number of voting rights and total numb…
|
English | 160.7 KB | ||
| 2022-10-20 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 129.2 KB | ||
| 2022-10-03 22:30 |
DBV Technologies Announces Appointment of New Chair of its Audit Committee and …
|
English | 197.9 KB | ||
| 2022-10-03 22:30 |
DBV Technologies annonce la nomination du nouveau Président de son Comité d’Aud…
|
French | 199.2 KB | ||
| 2022-09-21 23:45 |
DBV Technologies fait le point sur l’étude clinique de phase 3 VITESSE
|
French | 188.9 KB | ||
| 2022-09-21 23:45 |
DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial
|
English | 189.6 KB | ||
| 2022-09-07 22:30 |
DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modi…
|
English | 178.3 KB | ||
| 2022-09-07 22:30 |
DBV Technologies annonce le lancement de l’étude de phase 3 (VITESSE) portant s…
|
French | 189.5 KB | ||
| 2022-09-02 22:30 |
DBV Technologies to Present at Upcoming Investor Conferences
|
English | 128.9 KB | ||
| 2022-09-02 22:30 |
DBV Technologies invité à présenter lors des prochaines conférences investisseu…
|
French | 136.1 KB |
Automate Your Workflow. Get a real-time feed of all DBV Technologies filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for DBV Technologies
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DBV Technologies via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-09 | N/A | Other | Other | 2,483,161 | 7,449,483.00 EUR |
Peer Companies
